LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Search

Cytek Biosciences Inc

Slēgts

SektorsVeselības aprūpe

4.51 4.4

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.23

Max

4.57

Galvenie mērījumi

By Trading Economics

Ienākumi

-39M

-44M

Pārdošana

9.8M

62M

EPS

-0

Peļņas marža

-70.929

Darbinieki

702

EBITDA

4M

-263K

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+44.01% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-30M

531M

Iepriekšējā atvēršanas cena

0.11

Iepriekšējā slēgšanas cena

4.51

Ziņu noskaņojums

By Acuity

50%

50%

155 / 350 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Cytek Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. marts 18:34 UTC

Peļņas

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

2026. g. 19. marts 17:43 UTC

Galvenie tirgus virzītāji

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

2026. g. 19. marts 23:47 UTC

Peļņas

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

2026. g. 19. marts 23:47 UTC

Peļņas

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

2026. g. 19. marts 23:47 UTC

Peļņas

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

2026. g. 19. marts 23:47 UTC

Peļņas

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

2026. g. 19. marts 23:39 UTC

Peļņas

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

2026. g. 19. marts 23:39 UTC

Peļņas

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

2026. g. 19. marts 23:39 UTC

Peļņas

Li Ning: Outdoor Category Continued Growing >2331.HK

2026. g. 19. marts 23:38 UTC

Peļņas

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

2026. g. 19. marts 23:33 UTC

Tirgus saruna

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

2026. g. 19. marts 22:42 UTC

Iegādes, apvienošanās, pārņemšana

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

2026. g. 19. marts 22:42 UTC

Iegādes, apvienošanās, pārņemšana

McCormick Has a Market Value of Around $14.8B -- WSJ

2026. g. 19. marts 22:42 UTC

Iegādes, apvienošanās, pārņemšana

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

2026. g. 19. marts 22:42 UTC

Iegādes, apvienošanās, pārņemšana

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

2026. g. 19. marts 22:23 UTC

Tirgus saruna

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

2026. g. 19. marts 22:09 UTC

Tirgus saruna
Galvenie ziņu notikumi

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

2026. g. 19. marts 22:06 UTC

Tirgus saruna

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

2026. g. 19. marts 22:04 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

2026. g. 19. marts 22:03 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 19. marts 22:03 UTC

Tirgus saruna
Galvenie ziņu notikumi

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

2026. g. 19. marts 21:51 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

2026. g. 19. marts 20:57 UTC

Galvenie ziņu notikumi

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

2026. g. 19. marts 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 19. marts 20:19 UTC

Galvenie ziņu notikumi

Brent Crude Retreats After Touching $119 -- WSJ

2026. g. 19. marts 19:49 UTC

Tirgus saruna

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

2026. g. 19. marts 19:26 UTC

Galvenie ziņu notikumi

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

2026. g. 19. marts 19:10 UTC

Tirgus saruna
Galvenie ziņu notikumi

Natural Gas Rises in Volatile Trading -- Market Talk

2026. g. 19. marts 19:06 UTC

Galvenie ziņu notikumi

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

2026. g. 19. marts 18:08 UTC

Tirgus saruna
Galvenie ziņu notikumi

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cytek Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

44.01% augšup

Prognoze 12 mēnešiem

Vidējais 6.25 USD  44.01%

Augstākais 7.5 USD

Zemākais 5 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cytek Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

3.7 / 3.8Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

155 / 350 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat